Tbio ARIH1 E3 ubiquitin-protein ligase ARIH1

Protein Summary

Description

E3 ubiquitin-protein ligase, which catalyzes ubiquitination of target proteins together with ubiquitin-conjugating enzyme E2 UBE2L3 (PubMed:15236971, PubMed:21532592, PubMed:24076655, PubMed:27565346, PubMed:23707686). Acts as an atypical E3 ubiquitin-protein ligase by working together with cullin-RING ubiquitin ligase (CRL) complexes and initiating ubiquitination of CRL substrates: associates with CRL complexes and specifically mediates addition of the first ubiquitin on CRLs targets (PubMed:27565346). The initial ubiquitin is then elongated by CDC34/UBE2R1 and UBE2R2 (PubMed:27565346). E3 ubiquitin-protein ligase activity is activated upon binding to neddylated cullin-RING ubiquitin ligase complexes (PubMed:24076655, PubMed:27565346). Plays a role in protein translation in response to DNA damage by mediating ubiquitination of EIF4E2, the consequences of EIF4E2 ubiquitination are however unclear (PubMed:25624349). According to a report, EIF4E2 ubiquitination leads to promote EIF4E2 cap-binding and protein translation arrest (PubMed:25624349). According to another report EIF4E2 ubiquitination leads to its subsequent degradation (PubMed:14623119). Acts as the ligase involved in ISGylation of EIF4E2 (PubMed:17289916).

Uniprot Accession IDs

• Q9Y4X5
• B2R6U3
• O76026
• Q9H3T6
• Q9UEN0
• Q9UP39

Gene Name

• ARIH1

Ensembl ID

• ENST00000379887
• ENSP00000369217
• ENSG00000166233

Symbol

• ARI
• MOP6
• UBCH7BP
• ARI
• HARI
• HHARI
• UBCH7BP

Knowledge Table

Most Knowledge About	Knowledge Value (0 to 1 scale)
virus perturbation	1
disease perturbation	0.96
transcription factor binding site profile	0.95
histone modification site profile	0.78
transcription factor	0.64

Protein Classes

PANTHER Classes

Protein / Ligase / Ubiquitin-protein Ligase / E3 Ubiquitin-protein Ligase Arih1

DTO Classes

Protein / Enzyme / Ligase / Ubiquitin-protein Ligase / E3 Ubiquitin-protein Ligase Arih1

IDG Development Level Summary

Tdark

These are targets about which virtually nothing is known. They do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:

Pubmed score: 101.96   (req: < 5)

Gene RIFs: 13   (req: <= 3)

Antibodies: 98   (req: <= 50)

Tbio

These targets do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:

Pubmed score: 101.96   (req: >= 5)

Gene RIFs: 13   (req: > 3)

Antibodies: 98   (req: > 50)

- OR - satisfy the following criterion:

Gene Ontology Terms: 10

Tchem

Target has at least one ChEMBL compound with an activity cutoff of < 30 nM - AND - satisfies the preceding conditions

Active Ligand: 0

Tclin

Target has at least one approved drug - AND - satisfies the preceding conditions

Active Drug: 0